Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home

Not Applicable

• Conditions: Covid19
• Interventions: Biological: Ligilactobacillus salivarius MP101

• Registration Number: NCT04922918
• Lead Sponsor: Universidad Complutense de Madrid

Brief Summary

The objective of this work was to investigate the effect of Ligilactobacillus salivarius MP101 on the functional (Barthel index), cognitive (GDS/FAST) and nutritional (MNA) status, and on the nasal and fecal inflammatory profiles of elderly living in a nursing home highly affected by COVID-19.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-01
• Status Verified: 2021-06
• Study First Submitted: 2021-06-09
• Study First Submitted QC: 2021-06-09
• Last Update Submitted: 2021-06-09
• Study First Posted: 2021-06-11
• Last Update Posted: 2021-06-11
• Primary Completion: 2021-06-24
• Study Completion: 2021-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Living in the nursing home
• Informed consent obtained

Exclusion Criteria

• Absence of informed consent
• Parenteral nutrition (exclusively)
• Allergy to cow's milk protein

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Probiotic arm	Ligilactobacillus salivarius MP101	Administration of Ligilactobacillus salivarius MP101 (\>9 log10cfu, daily) for 4 months

Primary Outcome Measures

Name	Time	Method
MNA score	4 months	Nutritional status
Barthel index	4 months	functional status score (daily activities)
nasal and fecal immune profile	4 months	37-plex

Trial Locations

Locations (1)

Centro Para Mayores Santa Isabel, S.L.; 🇪🇸 Moralzarzal, Madrid, Spain